## **Product Data Sheet**

## PE/Cy7 anti-human EGFR

Catalog # / Size: 2364545 / 25 tests

2364550 / 100 tests

Clone: AY13

**Isotype:** Mouse IgG1, κ

Immunogen: Non-small cell lung cancer (NSCLC) cell

line NCI-H322

Reactivity: Human

**Preparation:** The antibody was purified by affinity

chromatography and conjugated with PE/Cy7 under optimal conditions. The solution is free of unconjugated PE/Cy7


and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide and

0.2% (w/v) BSA (origin USA).

Concentration: Lot-specific



Human cervical cancer cell line, Hela, was stained with EGFR (clone AY13) PE/Cy7 (filled histogram) or mouse IgG1, κ PE/Cy7 isotype control (open histogram).

## **Applications:**

**Applications:** Flow Cytometry

Recommended

Usage:

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for

each application.

Application References:

1. Yamaguchi M, et al. 2009. The 15th Annual Meeting Japan Society of Gene

es: Therapy. p1056. Abstract 92.

**Description:** Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and

member of the protein kinase superfamily that regulates cell growth and differentiation. EGFR binds EGF, TGF- $\alpha$ , amphiregulin,  $\beta$ cellulin, heparin-binding EGF-like growth factor, GP30, and vaccinia virus growth factor - all members of

the EGF family. Ligand binding induces EGFR dimerization and  $\,$ 

autophosphorylation, initiating the MAPK, Akt, and JNK signaling pathways. EGFR is expressed by epithelial and endothelial cells and is frequently expressed by

epithelial carcinomas.

Antigen References: 1. da Cunha Santos G. et al. 2011. Annu. Rev. Pathol. 6:49.

2. Gusterson BA and Hunter KD. 2009. Lancet Oncol. 10:522.

3. Mano M and Humblet Y. 2008. Nat. Clin. Pract. Oncol. 5:415.

4. Pao W and Chm